Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002608215 | SCV002943718 | uncertain significance | Long QT syndrome 10 | 2022-06-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with SCN4B-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change results in a frameshift in the SCN4B gene (p.Asn213Argfs*32). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 16 amino acid(s) of the SCN4B protein and extend the protein by 15 additional amino acid residues. |
Ambry Genetics | RCV003308169 | SCV004000792 | uncertain significance | Cardiovascular phenotype | 2023-06-12 | criteria provided, single submitter | clinical testing | The c.636_637dupGA variant, located in coding exon 5 of the SCN4B gene, results from a duplication of GA at nucleotide position 636, causing a translational frameshift with a predicted alternate stop codon (p.N213Rfs*32). This alteration is expected to result in protein truncation. However, loss of function of SCN4B has not been established as a mechanism of disease. The evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |